UPDATE - Rebel Capital 2.0 Corp. Enters Into Definitive Agreement With Alzex Biomedical Group Inc.HomeMailNewsFinanceSportsEntertainmentSearchMobileMore...YAHOO_FINANCESearchSign inMailSign in to view your mailFinance HomeWatchlistsMy PortfolioScreenersPremiumMarketsIndustriesPersonal FinanceVideosNewsTechU.S. Markets closedS&P 5002,978.76-137.63(-4.42%)Dow 3025,766.64-1,190.95(-4.42%)Nasdaq8,566.48-414.29(-4.61%)UPDATE - Rebel Capital 2.0 Corp. Enters Into Definitive Agreement With Alzex Biomedical Group Inc.GlobeNewswireJanuary 8, 2020ReblogShareTweetShareCALGARY, Alberta, Jan. 07, 2020 (GLOBE NEWSWIRE) -- Rebel Capital 2.0 Corp. ("Rebel" or the "Corporation") (RBZ-P.V) is pleased to announce that it has entered into a definitive agreement dated January 3, 2020 (the “Definitive Agreement”) with Alzex Biomedical Group Inc. (“Alzex”), a privately held corporation existing under the provisions of the Business Corporations Act (British Columbia) (the “BCBCA”), in furtherance of Rebel’s proposed business combination (the “Qualifying Transaction”) with Alzex all as previously disclosed in Rebel’s news release dated September 30, 2019, a copy of which, along with the Definitive Agreement, is available on Rebel’s company profile at www.sedar.com.Definitive Agreement Pursuant to the terms of the Definitive Agreement, a special-purpose subsidiary of Rebel will amalgamate with Alzex under the BCBCA (the “Amalgamation”) and Rebel (then, the “Resulting Issuer”) will carry on the business of Alzex under the name “Alzex Biomedical Group Inc.”.Immediately prior to the completion of the Amalgamation, Rebel will consolidate all of its issued and outstanding common shares (“Rebel Shares”) on the basis of one post-consolidation Rebel Share for every two pre-consolidation Rebel Shares. At the effective time of the Amalgamation (the “Effective Time”), each issued Alzex common share will be cancelled and replaced by one common share in the capital of the Resulting Issuer (a “Resulting Issuer Share”) and all other outstanding convertible securities of Alzex will become exercisable for Resulting Issuer Shares in accordance with the terms of the Definitive Agreement.Upon completion of the Qualifying Transaction, it is expected that the Resulting Issuer Shares will be composed of the following:37,925,863 common shares; Shares purchased through the Alzex Financing (as defined in the Definitive Agreement) of up to 10,000,000 Alzex Units (as defined in the Definitive Agreement) at a price of $0.25 per Alzex Unit for gross proceeds of $2,500,000, which shall close prior to the Amalgamation, and in any event, shall close no later than March 31, 2020.  Each Alzex Unit will be comprised of one common share and one whole share purchase warrant, each warrant exercisable for one Resulting Issuer Share at a price of $0.50 for a period of 24 months following closing of the Alzex Financing; and, Shares purchased in the Subscription Receipt Offering (as defined in the Definitive Agreement) of at least 8,333,333 units and up to 16,666,666 units at a price of $0.30 per unit for gross proceeds of between $2,500,000 and $5,000,000 whereby each subscription receipt shall be exchangeable into units of the Resulting Issuer.  Each Unit will be comprised of one common share and one whole share purchase warrant, each warrant exercisable for one Resulting Issuer Share at a price of $0.60 for a period of 24 months following closing of the Subscription Receipt Offering.Each of a, b and c above shall be completed in accordance with the terms of the Definitive Agreement and are subject to any regulatory, shareholder, director, TSX Venture Exchange (the “Exchange”) or other approvals that may be required.Trading Halt The Rebel Shares will remain halted from trading and the shares are not expected to resume trading until after completion of the Qualifying Transaction.Officers and Board of Directors of the Resulting IssuerUpon completion of the Qualifying Transaction, all directors and officers of Rebel shall resign and be replaced by nominees of Alzex. The following sets out the names and backgrounds of all persons who are currently expected to be considered directors and officers of the Resulting Issuer:Fabrice Heitzmann – Rouen, France - Chief Executive Officer (CEO) and DirectorMr. Heitzmann has over 21 years of experience in the pharmaceutical industry in France and abroad.  His experience includes contract and budget negotiations with customers, drafting product development studies/strategies, and managing clinical studies.  He began his career in 1998 as a Chemical Buyer for Synkem SAS manufacturer and supplier of active pharmaceutical ingredients.  He then moved to more senior supply chain and procurement roles at Fournier Laboratories Ireland Ltd., Rhone Poulenc Biochimie AS, and Sanofi S.A.  In addition to his current role with Alzex, Mr. Heitzmann also serves as the Vice President of Global Resources for Chrysalis Pharma Partners, LLC, a drug development consulting company and Senior Procurement Consultant of BuyingPeers SAS, a procurement and sourcing consulting firm based in Paris.  Mr. Heitzmann also serves as general Manager of Clemann Group, a global resources management consulting firm for biotechnology firms and start-ups.  He obtained his master’s degree in molecular biology, biochemistry, and cell biology from the University of Burgundy and his doctorate in life sciences from the University of Claude Bernard.  Mr. Heitzmann’s experience and background in the pharmaceutical industry are beneficial to the Company as he has experience in identifying sourcing and procurement opportunities in the pharmaceutical industry, preparing clinical development plans, and managing clinical studies.Scott Davis – Vancouver, British Columbia - Chief Financial Officer (CFO)Mr. Davis is a partner of Cross Davis & Company LLP Chartered Professional Accountants, a firm focused on providing accounting and management services for publicly-listed companies.  His experience includes CFO positions of several companies listed on the Canadian Securities Exchange and the Exchange.  His past experience consists of senior management positions, including four years at Appleby as an Assistant Financial Controller, two years at Davidson & Company LLP Chartered Professional Accountants as an Auditor and five years with Pacific Opportunity Capital Ltd. as an Accounting Manager.Story continuesIt is anticipated that an additional 2 individuals will be appointed to the board of directors of the Resulting Issuer prior to closing.Further InformationFurther information in respect of the Qualifying Transaction and the Resulting Issuer will be provided in the filing statement (the “Filing Statement”) to be prepared in connection with the Qualifying Transaction and filed on Rebel’s company profile at www.sedar.com.Additional terms of the Qualifying Transaction including consideration payable pursuant to the Qualifying Transaction, information relating to sponsorship (if applicable), summary financial information in respect of Alzex, the controlling shareholders of Alzex, and to the extent not contained in this press release, additional information with respect to the history  of Alzex and the proposed  directors,  officers,  and  insiders  of the  Resulting Issuer upon  completion  of the  Qualifying Transaction.Investors are cautioned that, except as disclosed in the Filing Statement, any information released or received with respect to the Qualifying Transaction may not be accurate or complete and should not be relied upon. Trading in Rebel Shares should be considered highly speculative.All information contained in this news release with respect to Rebel and Alzex was supplied by the parties respectively for inclusion herein, and each party and its directors and officers have relied on the other party for any information concerning the other party.Completion of the Qualifying Transaction is subject to a number of conditions, including but not limited to, Exchange acceptance and if applicable pursuant to Exchange Requirements, majority of the minority shareholder approval. Where applicable, the transaction cannot close until the required shareholder approval is obtained. There can be no assurance that the transaction will be completed as proposed or at all.Investors are cautioned that, except as disclosed in the management information circular or filing statement to be prepared in connection with the Qualifying Transaction, any information released or received with respect to the Qualifying Transaction may not be accurate or complete and should not be relied upon. Trading in the securities of a capital pool company should be considered highly speculative.For further information please contact:Rebel Capital 2.0 Corp.:Charles MaLette,Email: bud@criticalco2.caTelephone: (604) 428-5171Alzex Bio Medical Inc.:Fern Turner – VP Corporate Communications and Director Email: fern@alzex.caCautionary StatementsThis news release contains “forward-looking information” within the meaning of applicable securities laws relating to the proposal to complete the Qualifying Transaction and associated transactions, including statements regarding the terms and conditions of the Qualifying Transaction, the Alzex Financing, the Subscription Receipt Offering, and the Consolidation and the Name Change. The information about Alzex contained in the press release has not been independently verified by Rebel. Although Rebel believes in light of the experience of its officers and directors, current conditions and expected future developments and other factors that have been considered appropriate that the expectations reflected in this forward-looking information are reasonable, undue reliance should not be placed on them because Rebel can give no assurance that they will prove to be correct. Readers are cautioned to not place undue reliance on forward-looking information. Actual results and developments may differ materially from those contemplated by these statements depending on, among other things, the risks that the parties will not proceed with the Qualifying Transaction, the Alzex Financing, the Subscription Receipt Offering, the Consolidation, the Name Change and associated transactions, that the ultimate terms of the Qualifying Transaction, the Alzex Financing, the Subscription Receipt Financing, the Consolidation and the Name Change and associated transactions will differ from those that currently are contemplated, and that the Qualifying Transaction, the Alzex Financing, the Subscription Receipt Offering, the Consolidation, the Name Change and associated transactions will not be successfully completed for any reason (including the failure to obtain the required approvals or clearances from regulatory authorities). The terms and conditions of the Qualifying Transaction may change based on Rebel’s due diligence (which is going to be limited as Rebel intends largely to rely on the due diligence of other parties of the Qualifying Transaction to contain its costs, among other things) and the receipt of tax, corporate and securities law advice for both Rebel and Alzex. The statements in this press release are made as of the date of this release. Rebel undertakes no obligation to comment on analyses, expectations or statements made by third-parties in respect of Rebel, Alzex, their securities, or their respective financial or operating results (as applicable).Neither the TSX Venture Exchange, Inc. nor its Regulation Services Provider (as that term is defined in the polices of the TSX Venture Exchange) has in any way passed upon the merits of the Qualifying Transaction and associated transactions and neither of the foregoing entities has in any way approved or disapproved of the contents of this press release.Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.The common shares have not been and will not be registered under the United States Securities Act of 1933, as amended and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirement. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.ReblogShareTweetShareRecently ViewedYour list is empty.What to Read NextToronto Stock Exchange Gets ‘Black Eye,’ Closes Early In RoutBloombergBiocontainment expert on coronavirus: There's no need for average people to panic yetYahoo FinanceA drug shortage due to the coronavirus is a 'considerable risk:' Fmr. FDA deputy commissionerYahoo Finance VideoStock market live updates: Dow drops 1190 points amid coronavirus fears, S&P 500 sees fastest correction in historyYahoo FinanceAmid coronavirus, bitcoin has fallen 6% this week to below $8,800Yahoo FinanceEl-Erian: The Fed will cut rates in March, if not beforeYahoo Finance Video'Stuck in no man’s land': A working mom details dealing with her sick child's student loan billYahoo FinanceMost face masks won’t protect you from the coronavirusYahoo FinanceRichard Branson’s Wealth Falls to Earth as Virgin Galactic SputtersBloombergCoronavirus-induced stock selloff means IPO market is 'on holiday': veteran IPO analystYahoo FinanceMarket Watcher: Over six months we will see the markets higher Yahoo Finance VideoStock market live updates: Stock futures climb after historic rout; coronavirus fears persistYahoo FinanceDon’t buy the stock dip yet, says Goldman as it warns coronavirus will wipe out earnings growth this yearMarketWatchThis company is revamping presentation softwareYahoo Finance VideoBeyond Meat beats on Q4 earnings, founder says 'we would be crazy not to invest in growth right now'Yahoo FinanceWhat to watch in the markets: Friday, February 28Yahoo Finance VideoBusinessTheStreet.comHere's When You Should Buy Stocks AgainThe S&P 500 kicked off the week Monday by gapping down 2.4%, the worst opening gap lower for the broad index since 1982. And it's followed up with consistent selling, putting the broad market on track for its worst week since the financial crisis of 2008. Is this finally the end of the rally that's propelled stocks more than 80% higher on a total-return basis over the past four years?BusinessYahoo FinanceStock market live updates: Stock futures climb after historic rout; coronavirus fears persistOn Thursday evening shortly after 6 p.m. ET, Dow futures (YM=F) were down 0.3%, S&P futures (ES=F) were down 0.4%, and Nasdaq futures (NQ=F) were down 0.3%. “Global markets were down $1.83 trillion today, with the U.S. down $1.33 trillion,“ S&P Dow Jones' Howard Silverblatt said in an email.BusinessUSA TODAYCoronavirus fears spook stocks: Here's how to keep a cool head and protect your 401(k)Sign up here Here are four moves experts say could help protect your investments during volatile periods, such as the bumpy stretch caused by the coronavirus: 401(k): Coronavirus fears shouldn't stop you from investing in stocks Monitoring markets: Dow jumps 300 points as investors assess economic fallout from virus 1. Review your investments Pay attention to where you're invested and which companies are most likely to be affected, portfolio managers say. Daniel Milan, managing partner at Southfield, Michigan-based Cornerstone Financial Services, says the effects from the virus outbreak on the stock market will be short-lived and has cautioned his clients to not let fear drive their investme...BusinessYahoo FinanceStock market live updates: Dow drops 1190 points amid coronavirus fears, S&P 500 sees fastest correction in historyGlobal financial markets plunged for the sixth consecutive day on Thursday, with coronavirus fears shaving over 1,100 points off the Dow (^DJI) — its biggest in history — and sending the S&P 500 (^GSPC) swooning to its fastest-ever correction. Global markets were down $1.83 trillion today, with the U.S. down $1.33 trillion,“ S&P Dow Jones' Howard Silverblatt said in an email. He added that over the past six days, global markets erased $6 trillion in wealth with U.S. markets losing $4 trillion.BusinessInvestor's Business DailyDow Jones Futures Fall Sharply As Coronavirus Stock Market Correction Intensifies; Tesla, Nvidia, Beyond Meat Down LateDow Jones futures plunged Thursday, along with S&P 500 futures and Nasdaq futures. The coronavirus stock market correction intensified Thursday, with the Dow Jones and other major indexes all falling more than 4%. The U.S. is monitoring thousands of people in California for possible Covid-19 infections, while coronavirus cases continued to spread.BusinessYahoo FinanceSomething 'dangerous' is happening beneath the surface of the market selloffSo every time stocks went up, bonds tailed off and vice-versa,” Academy Securities' Peter Tchir said on Yahoo Finance's The Final Round. All of a sudden, that behavior changed a little bit into the close yesterday. And making it even more dangerous to me, you saw oil fall off into the close.BusinessYahoo Finance VideoWhat to watch in the markets: Friday, February 28After yet another volatile day of trading on Wall Street, Yahoo! Finance's Myles Udland discusses what to watch in the markets tomorrow,BusinessBloombergHow to Tell When Markets Finally Reach a BottomOr, when current Federal Reserve Chair Jerome Powell made his “dovish pivot” in January 2019 by saying the central bank would be “patient and flexible” when it came to considering future interest-rate increases. But what makes the current plunge different is that it's being driven by an event — the threat that the coronavirus will become worldwide pandemic — that is out of the control of monetary policy makers and Wall Street. So, there is unlikely to be some “magic” headline that scrolls across the computer screens of investors and traders that says it is over.BusinessMarketWatchWait for these signals to buy coronavirus-battered stocks, says BNY Mellon strategistSome believe the next big fall in equities will come when we see a cluster of U.S. cases, which may partly explain why that popular past time of buying stocks on any dip seems less popular lately. Citigroup strategists are advising against buying equities right now, on the view that if a Federal Reserve lifeline is coming, it may not happen right away. Gov. Warsh argues for immediate, globally coordinated rate cut Our call of the day comes from BNY Mellon's chief strategist Alicia Levine, who has advice for those wanting to know when to buy beaten-down (and down) stocks.BusinessMarketWatchStock-market plunge ‘starting to feel a bit ridiculous,’ but don’t argue, says chart-watcherIt doesn't pay to fight the tape, but the stock market could be poised for a big-time rally once the current selloff subsides, a veteran chart-watcher said Thursday. “This move lower is starting to feel a bit ridiculous, but we try not to argue with Ms. Market,” said Mark Arbeter, president of Arbeter Investments, in a note. “If and when this thing turns, we should see some rip-roaring rally.”BusinessYahoo Finance CanadaTrading halted on TSX, citing order entry issueTrading on the TSX and TMX's other exchanges has been halted for the rest of the day as TMX investigates an order entry problem on its exchanges. A technical halt has been declared on TSX, TSXV & TSX Alpha,” said TMX in a statement posted to Twitter. In order to allow Participants to manage their orders, the market will remain in a Pre-Open state until further notice.BusinessMarketWatchThese stocks have been crushed since the coronavirus began to take down the U.S. marketa href="https://www.marketwatch.com/story/these-stocks-have-been-crushed-since-the-coronavirus-began-to-take-down-the-us-market-2020-02-27? siteid=yhoof2" (DVN) Oil & Gas Production -31.0% -39.7% -55.7% 15.2% Royal Caribbean Cruises Ltd.BusinessYahoo FinanceBeyond Meat beats on Q4 earnings, founder says 'we would be crazy not to invest in growth right now'The company notched blistering sales growth in its retail (198%) and food service/restaurant segments (223%). Unclear if analysts will ding Beyond Meat for slowing sales growth at each segment compared to the third quarter. Beyond Meat founder and CEO Ethan Brown tells Yahoo Finance the quarter was “outstanding.”BusinessTheStreet.comJim Cramer on Coronavirus: What It Means for Markets, Federal Reserve and MicrosoftJim Cramer has some thoughts on the markets, the Federal Reserve and Microsoft as coronavirus fears shake Wall Street. Stock futures declined sharply Thursday, putting Wall Street on pace for its worst week since the global financial crisis in 2008, as coronavirus infections accelerated and health officials confirmed that a California man contracted the disease despite having no travel links or contacts with those afflicted by the virus. The company warned investors that it will fall short of previously issued fiscal third-quarter sales guidance of between $10.75 billion and $11.15 billion for its "more personal computing" segment, which includes Windows OEM and Surface.BusinessYahoo Finance VideoTrending Ticker: VIR Surges as Coronavirus fears persistAs the markets continue to fall, the biotech field is seeing a boost as companies race to develop vaccines and a cure. Vir Biotechnology Inc. shares surged over 60%, while Gilead Sciences stocks saw a bump of 4%.BusinessInvestor's Business DailyProtective Mask Maker Soars 340% This Week As Coronavirus SpiralsAlpha Pro Tech announced a spike in face mask orders amid the spiraling coronavirus outbreak, a day after disclosing earnings for the fourth quarter. APT stock soared, also boosting Lakeland Industries and Dow Jones Industrial Average component 3M. APT said Thursday it has booked about $14.1 million face mask orders since Jan. 27. That is up from the $10.4 million APT had reported just two weeks ago on Feb. 13.BusinessMarketWatchTrump talks about the stock market, and gets 1 out of 3 points rightStock markets do this all the time. Since Trump was elected president in November 2016, the Dow has risen from around 18,000 to around 27,000. Trump went on an extended riff blaming the market's fall on Tuesday's Democratic presidential debate.BusinessYahoo FinanceCoronavirus just sent the Dow crashing 1,100 points and it could get worseThe disturbing coronavirus driven selloff across global stock markets this week may be the tip of the iceberg for one simple reason. Stocks have yet to price in a mild — or somewhat bruising — recession in the U.S. as coronavirus infection cases pile up and bring consumer activity and businesses to a standstill. Up until now, equity strategists Yahoo Finance have talked with, say the stock market's six-day drubbing largely reflects de-leveraging by hedge funds and speculators on momentum names (see Microsoft, Apple, etc.).BusinessInvestor's Business Daily'What's Going On, Moderna?' Investors Ask As Shares Go On A Wild RideModerna took biotech investors on a ride Thursday as MRNA stock rocketed, was halted and then plunged in a matter of hours. On the stock market today, MRNA stock toppled 10.3%, to 26.16. But in the early morning, shares of the biotech company skyrocketed more than 23% to a fresh high at 36.BusinessBarrons.comCoronavirus Means More Risk for Chip Stocks, Says Analyst. It May Be Time to Buy These 3.There is likely more pain ahead for the semiconductor sector, but Bernstein analyst Stacy Rasgon says investors should get ready to buy some names on the dip. Chip stocks have tumbled this past week, along with equity markets, as the coronavirus spreads outside of China. The (SOXX), which tracks the performance of a widely followed semiconductor-sector index, has declined by about 10% this week, compared with the 9% drop for the S&P 500.Tesla slumps on Morgan Stanley downgradeYahoo Finance VideoSomething 'dangerous' is happening beneath the surface of the market selloffYahoo FinanceTalkspace connects people with licensed therapistsYahoo Finance VideoCoronavirus won't stop Beyond Meat from entering China in 2020: CEO Ethan BrownYahoo FinanceBreaking down how China’s GDP goals will be impacted by the coronavirusYahoo Finance Video'Frozen 2' sets Thanksgiving weekend record with $123 million box officeYahoo Finance VideoTrump brand 'has become toxic' for some people, Forbes editor saysYahoo FinanceCoronavirus will wipe out corporate profit growth in 2020 and may trigger recession: Goldman SachsYahoo FinanceWall Street cites Bernie Sanders as a rival to the coronavirus as a market riskYahoo FinanceBeyond Meat shares surge, then tumble, after reporting earningsYahoo Finance VideoStock Market Live Updates: Stocks end little changed, lashed by Brexit and US-China tradeYahoo FinanceParalee Boyd Salon in Detroit, Michigan is now beginning to offer franchises of the businessYahoo Finance VideoWhy economic inequality in the U.S. is at the highest level in 50 yearsYahoo Finance VideoTrending Ticker: VIR Surges as Coronavirus fears persist Yahoo Finance VideoWhy companies turn to data to drive their businessesYahoo Finance VideoCoronavirus-canceled events: A rolling list of scrapped plans amid the outbreakYahoo Finance